Checkout View Cart Items

Human T Cell Activation and Expansion

Ready-to-use Dynabeads® allows for simultaneous signalling to TCR/CD3 and CD28 for physiological activation and expansion of human T cells.

See our new product for expansion of human antigen specific T cell lines or clones Dynabeads® Human T-Activator CD3/CD28/CD137

This technology out-performs traditional home-brew activation methods (mitogens, ConA, soluble antibodies etc.), and is well documented in the published literature.
Dynabeads® allow you to move from mouse studies to clinical research using the same technology platform for activation/expansion .

Here's a short overview of the available products. For a more complete overview, check out this Product Selection Guide (pdf).
Product Starting sample Main benefits
Dynabeads® Human
T-Activator CD3/CD28 (0.4 ml)
MNC, CD3+ T cells, CD4+ or CD8+ T cell subsets, T cell clones Activate and expand naïve T cells, activated T cells, T cell clones and memory T cells
Dynabeads® Human
T-Activator CD3/CD28
(2 ml)
MNC, CD3+ T cells, CD4+ or CD8+ T cell subsets, T cell clones Activate and expand naïve T cells, activated T cells, T cell clones and memory T cells
Dynabeads® Human
T-Activator CD3/CD28
(10 ml)		MNC, CD3+ T cells, CD4+ or CD8+ T cell subsets, T cell clones Activate and expand naïve T cells, activated T cells, T cell clones and memory T cells
Dynabeads® Human Treg Expander Treg cells isolated from whole blood, buffy coat or MNC Expand regulatory T cells while retaining suppressive phenotype and capacity.
Dynabeads® Human
T-Expander CD3/CD28 		Leukopheresis or MNC from buffy coat or whole blood This is the research version of Dynabeads® ClinExVivo™
Dynabeads®Human T-Activator CD3/CD28/CD137
T cell line or clone.
Isolated/enriched Ag-specific T cells
CD137 adds an additional costimulatory signal which prolongs survival and increases proliferation of memory T cells
Dynabeads® ClinExVivo™ CD3/CD28 Leukopheresis or MNC from buffy coat or whole blood For ex vivo isolation and expansion of CD3+ T cells in clinical research. Up to 1,000-fold expansion in 14 days while preserving optimal immunobiological properties.

References

  • The references listed below are among the many published papers documenting the performance of the Dynabeads® technology for T cell activation and expansion:

    1. Berger, C. et al. (2003) CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy.Blood 101:476–484.
    2. Bonyhadi, M. et al. (2005) In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol 174:2366–2375.
    3. Hami, L. et al. (2003) Comparison of a static process and a bioreactor-based process for the GMP manufacture of autologous Xcellerated T cells for clinical trials. BioProcessing Journal Vol. 2 No. 6, November/December 2003.
    4. Levine, B.L. et al. (2002) Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreases CCR5 expression in HIV infection. Nat Med 8:47–53.
    5. Godfrey, W.R. et al. (2004) In vitro expanded human CD4+CD25+ T regulatory cells can markedly inhibit allogeneic dendritic cell stimulated MLR cultures. Blood 104:453–461.
    6. Coito, S. et al. (2004) Retrovirus-mediated gene transfer in human primary T lymphocytes induces an activation-and transduction/selection-dependent TCRBV repertoire skewing of gene-modified cells. Stem Cells Dev 13:71–81.
    7. Rapoport, A.P. et al. (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 11:1162–1163.
Feedback Form